Innovation and Market Exclusivity in the EU, PharmTech

Partner Jackie Mulryne spoke with PharmTech about the European Union’s sweeping update to its pharmaceutical legislation and the implications for drug developers.

“The most highly contested and most discussed element of the reform has always been the regulatory protections for innovative medicinal products,” Jackie commented.

Read the full PharmTech article >>